Medicare beneficiaries whose physicians participate in accountable care organizations (ACOs), particularly those taking on financial risk for cost and quality, receive substantially more primary and ...

Margaret Krackeler, MD, of Kaiser Permanente Northern California, discusses the growing role of real-world treatment data in CLL and other cancers.

Objective: To address concerns about payment adequacy in Medicare Advantage (MA) plans, a 2017 federal policy change increased risk scores and associated capitated payments for community-dwelling ...

Experts discuss the challenges of integrating new cancer therapies, addressing multidisciplinary care, evolving guidelines, and the financial burden on patients.

Experts discuss the potential of TKIs like zongertinib and seviberatinib as first-line treatments for HER2-mutant non-small cell lung cancer.

Nurse navigators play a crucial role in managing HER2-targeted therapy side effects, ensuring patient education and early toxicity detection.

Experts discuss the promising future of HER2-targeted therapies, highlighting new treatments and combination strategies for ...

PBMs typically receive a portion of rebates paid by drug manufacturers, the majority of which are passed back to the payer as an incentive to prefer a drug on a formulary. PBMs may also retain revenue ...

The Maui Derm 2026 meeting featured in-depth discussion surrounding all areas of dermatology. Here, The American Journal of Managed Care ® asked speakers and attendees what their ...

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges ...

Telomere length and polygenic risk scores (PRS) are linked to idiopathic pulmonary fibrosis (IPF) risk, especially in noncarriers of rare genetic variants. The study identified rare damaging variants ...

Oncodermatology is evolving with nonsurgical approaches and immune checkpoint inhibitors, improving outcomes in aggressive ...